Listed

Amneal Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2018

Filed with the SEC on Mar 1, 2019 and accepted by EDGAR at Mar 1, 2019, 08:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-10-01 to 2018-12-31$497.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2018-01-01 to 2018-12-31$1.66bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2018-01-01 to 2018-12-31$946.6mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-10-01 to 2018-12-31$193.4mus-gaap:GrossProfit
Gross profit12 months2018-01-01 to 2018-12-31$716.4mus-gaap:GrossProfit
Research and development12 months2018-01-01 to 2018-12-31$194.2mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2018-01-01 to 2018-12-31$230.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2018-01-01 to 2018-12-31−$19.7mus-gaap:OperatingIncomeLoss
Income tax12 months2018-01-01 to 2018-12-31−$1.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-10-01 to 2018-12-31−$20.3mus-gaap:ProfitLoss
Net income12 months2018-01-01 to 2018-12-31−$19.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-10-01 to 2018-12-31−$0.07us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-10-01 to 2018-12-31−$0.07us-gaap:EarningsPerShareBasic
Operating cash flow12 months2018-01-01 to 2018-12-31$250.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2018-01-01 to 2018-12-31$83.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid12 months2018-01-01 to 2018-12-31$183.0mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2018-12-31$213.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-12-31$1.29bnus-gaap:AssetsCurrent
Total assetsAt period end2018-12-31$4.35bnus-gaap:Assets
Current liabilitiesAt period end2018-12-31$553.9mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2018-12-31$2.63bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-12-31$21.4mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2018-12-31$504.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001723128-19-000028. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.